This session will for the very first time present the Swedish drug development pipeline at the BIO International Convention and demonstrate why Sweden is one of the most interesting locations outside the United States when it comes to product development and innovation. A top selection of Swedish and international decision makers from industry, academia, health care and government will share their perspectives on what they are doing to harvest these values and bring new products to patients.

Objective1:Demonstrate the extent of the Swedish drug development pipeline in preclinical and clinical development, their partnering status, indications and stages of development.

Objective2:Discuss the origin of this innovation and the strengths and opportunities.

Objective3:Promote the opportunities for biotechnology and pharmaceutical companies to meet and interact with Swedish institutions and companies.